Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)Deborah Bradley, Maha Hussain, Howard I. Scher et al.|Cancer|2009Cited by 148
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.Bruce Ruggeri, Craig A. Dionne, Diane E. Gingrich et al.|PubMed|2003Cited by 124
Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine ModelsLi Shen, Роберто Пили, Anette Sundstedt et al.|Cancer Immunology Research|2014Cited by 90
Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancerJohn T. Isaacs, Tomas Leanderson, Роберто Пили et al.|The Prostate|2006Cited by 87